Vanguard Capital Management
IGC icon

Vanguard Capital Management’s IGC Pharma IGC Stock Holding History

Vanguard Capital Management’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
814,914
+96,478
+13% +$28.5K ﹤0.01% 3810
2026
Q1 		$189K Buy
+718,436
New +$199K ﹤0.01% 3804

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's IGC Position: Q2 2026 in Review

Vanguard Capital Management increased its IGC Pharma (IGC) stake by 13% in Q2 2026, buying an estimated $28.5K and bringing the position to 814,914 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Vanguard Capital Management first reported a position in IGC in Q1 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

  • Vanguard Capital Management held 814,914 shares of IGC Pharma worth $222K as of Q2 2026.
  • Vanguard Capital Management bought 96,478 IGC Pharma shares in Q2 2026, an estimated $28.5K.
  • IGC Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3810 holding.
  • Vanguard Capital Management first reported a position in IGC Pharma in Q1 2026 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.